About Point Biopharma
Founded in late 2019, POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.
Radioligands are safe and effective cancer treatments that have been used for many years to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumours, thyroid cancer and, most recently, prostate cancer.
Compared to chemotherapy, which can cause extensive damage to healthy cells, radioligands precisely deliver a radioactive payload that kills cancer cells and leaves surrounding healthy cells untouched. The immune system is then mobilized to the site of disease, amplifying the therapeutic effect.
Our objective is to provide the right medicine at the right time for the right patient. By combining radioligands with companion molecular imaging agents and PET/CT, physicians can make informed treatment decisions and select patients that will respond to treatment for the best outcomes.
Investors and Partners
POINT Biopharma has developed deep expertise in radiopharmaceutical trials, manufacturing and commercial deployment. We continue to look for assets and partners with unique expertise and innovative platforms.